Search Results

Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.

Athos Therapeutics, Inc. (“Athos”) announced today that it has been granted a CTN acknowledgement from the Australian Therapeutic Goods Administration and has received Human Research Ethics Committee (“HREC”) approval to commence a Phase I clinical trial of ATH-063 in Australia.

Athos Therapeutics, Inc. (“Athos”) is a late-stage preclinical biotech company using Artificial Intelligence (AI) to develop small molecule therapeutics for immune-mediated diseases and cancer.

Athos Therapeutics, Inc. (“Athos”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today a comprehensive Master Research Agreement for a collaborative project on Inflammatory Bowel Disease (IBD) with Lahey Hospital & Medical Center (“Lahey”).

Athos Therapeutics, Inc. announced today the completion of an oversubscribed $15MM Series A financing.

Athos Therapeutics, Inc. (the “Company”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today that Yiannis Monovoukas , PhD, MBA, and Monte Stettin were appointed as advisors and observers to the Board of Directors.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment of €188 million led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne.

Athos Therapeutics, Inc., a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced that Abraham Verghese, MD, MACP has been named to the Company’s Board of Directors.